Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This trial will study tisotumab vedotin to find out whether it is an effective treatment for
certain solid tumors and what side effects (unwanted effects) may occur. There are three
parts to this study. In Part A, the treatment will be given to participants every 3 weeks
(3-week cycles). In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15
every 4-week cycle. In Part C, participants may receive tisotumab vedotin on Days 1 and 15 or
Days 1, 8, and 15 on a 4-week cycle.